单剂米非司酮暴露在美国中毒中心的临床结局:2015-2024年全国中毒数据系统十年回顾
该研究回顾了2015年1月1日至2024年12月31日美国国家中毒数据系统报告的106例单剂米非司酮暴露,77例符合纳入标准。患者平均年龄18.1岁(范围5个月-71岁),76.6%为女性,10.3%为孕妇。多数为急性(93.5%)、非故意(64.9%)口服摄入(94.8%)。最常见效应为恶心或呕吐(7.8%)、腹痛(5.2%)、头晕或眩晕(3.9%)。无主要效应、重症监护入院或死亡,孕妇中无胎儿死亡或显著母体并发症。
要点
- 单剂米非司酮暴露的77例中,无主要效应、无重症监护入院、无死亡。
- 最常见临床效应为恶心或呕吐(7.8%)、腹痛(5.2%)、头晕或眩晕(3.9%)。
- 10.3%的暴露者为孕妇,未报告胎儿死亡或显著母体并发症。
- 64.9%为非故意暴露,93.5%为急性暴露,94.8%为口服摄入。
- 8例(10.3%)孕妇中无胎儿死亡或显著母体并发症报告。
适用人群与场景
- 单剂米非司酮暴露的患者,包括儿童(≤12岁)和青少年/成人(>12岁)。
- 排除共暴露、复方产品或无关结局的病例。
处置流程与药物剂量
- 最常见的治疗为稀释或冲洗(13%)、静脉输液(2.6%)、类固醇(2.6%)和抗组胺药(2.6%)。
研究设计与关键结果
- 研究类型为回顾性审查,样本量106例单剂米非司酮暴露,77例符合纳入标准。
- 平均年龄18.1岁(范围5个月-71岁),76.6%为女性,10.3%为孕妇。
- 多数暴露为急性(93.5%)、非故意(64.9%)、口服摄入(94.8%)。
- 最常见效应:恶心或呕吐(7.8%)、腹痛(5.2%)、头晕或眩晕(3.9%)。
- 2例患者入住非重症监护病房,无主要效应或死亡。
- 孕妇中无胎儿死亡或显著母体并发症报告。
证据类型、等级与局限
- 证据类型:回顾性审查。
- 局限:原文未报告局限性。
对床旁实践的改变
- 单剂米非司酮暴露通常表现为轻度、自限性症状,无需重症监护干预。
- 作者认为单剂米非司酮暴露罕见导致主要效应,临床过程通常良性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Mifepristone is a 19-nor steroid that functions as a progesterone and glucocorticoid receptor antagonist with multiple uses approved by the United States Food and Drug Administration. Although its safety with therapeutic use is well established, data describing single-agent mifepristone toxicity is limited.
METHODS: This was a retrospective review of single-agent mifepristone exposures reported to the National Poison Data SystemⓇ from 1 January 2015, through 31 December 2024. Cases involving co-exposures, combination products, or unrelated outcomes were excluded. Demographic characteristics, exposure circumstances, clinical effects, management sites, therapies, and outcomes were analyzed using descriptive statistics.
RESULTS: Of 106 single-agent mifepristone exposures misoprostol identified, 77 patients met inclusion criteria. Patients were categorized as children ≤12 years old or adolescents/adults >12 years old. The mean patient age was 18.1 years (range 5 months-71 years), and 76.6% were female. Eight patients (10.3%) were pregnant. Most exposures were acute (93.5%), unintentional (64.9%), and occurred by oral ingestion (94.8%). The most common effects were nausea or vomiting (7.8%), abdominal pain (5.2%), and dizziness or vertigo (3.9%). The most common therapies were dilution or irrigation (13%), intravenous fluids (2.6%), steroids (2.6%), and antihistamines (2.6%). Two patients were admitted to non-critical care units, and there were no major effects or deaths. Among pregnant patients, no fetal deaths or significant maternal complications were reported.
DISCUSSION: Mifepristone exposures reported to United States poison centers in our study were uncommon and typically associated with mild, self-limited symptoms. No major effects, critical care admissions, or deaths were identified.
CONCLUSION: These findings suggest that single-agent mifepristone exposures rarely result in major effects and generally follows a benign clinical course.
参考来源
- Arens AM, Olinde A, Knowles T, et al. Clinical outcomes of single-agent mifepristone exposures reported to US Poison Centers: a ten-year review of the National Poison Data System® (2015-2024). Clin Toxicol (Phila). 2026. PMID: 41891345. doi:10.1080/15563650.2026.2642217
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。